BBIO
BridgeBio Pharma, Inc.
28.99
USD
This page is just a preview of the data found in TrendSpider’s full version
BridgeBio Pharma, Inc. stock is up 13.64% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 6 CALLs, 4 PUTs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 07 Nov 20:02 | 17 Jan, 2025 | 25.00 | 784 | ||
| 07 Nov 20:08 | 17 Jan, 2025 | 35.00 | 7768 | ||
| 07 Nov 20:08 | 17 Jan, 2025 | 25.00 | 784 | ||
| 07 Nov 20:17 | 17 Jan, 2025 | 25.00 | 784 | ||
| 08 Nov 14:32 | 17 Jan, 2025 | 35.00 | 2871 | ||
| 08 Nov 14:33 | 17 Jan, 2025 | 35.00 | 2871 | ||
| 08 Nov 14:55 | 17 Jan, 2025 | 35.00 | 7912 | ||
| 10 Nov 17:34 | 17 May, 2024 | 35.00 | 1 | ||
| 15 Nov 15:33 | 16 Feb, 2024 | 35.00 | 134 | ||
| 17 Nov 20:25 | 17 Jan, 2025 | 50.00 | 2639 |
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a stabilizer of transthyretin, or TTR.
